| BOHOŠOVÁ, Júlia, Jaroslav JURÁČEK, Alexandr POPRACH, J. KOPECKY, O. FIALA, Marek SVOBODA, Pavel FABIAN, Lenka RADOVÁ, Petr BRABEC, T. BUCHLER and Ondřej SLABÝ. MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients. CANCER GENOMICS & PROTEOMICS. ATHENS: INT INST ANTICANCER RESEARCH, 2019, vol. 16, No 5, p. 353-359. ISSN 1109-6535. Available from: https://dx.doi.org/10.21873/cgp.20140. |
Other formats:
BibTeX
LaTeX
RIS
@article{1616997,
author = {Bohošová, Júlia and Juráček, Jaroslav and Poprach, Alexandr and Kopecky, J. and Fiala, O. and Svoboda, Marek and Fabian, Pavel and Radová, Lenka and Brabec, Petr and Buchler, T. and Slabý, Ondřej},
article_location = {ATHENS},
article_number = {5},
doi = {http://dx.doi.org/10.21873/cgp.20140},
keywords = {Renal cell carcinoma; sunitinib; microRNA; prediction},
language = {eng},
issn = {1109-6535},
journal = {CANCER GENOMICS & PROTEOMICS},
title = {MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients},
url = {http://cgp.iiarjournals.org/content/16/5/353.full},
volume = {16},
year = {2019}
}
TY - JOUR
ID - 1616997
AU - Bohošová, Júlia - Juráček, Jaroslav - Poprach, Alexandr - Kopecky, J. - Fiala, O. - Svoboda, Marek - Fabian, Pavel - Radová, Lenka - Brabec, Petr - Buchler, T. - Slabý, Ondřej
PY - 2019
TI - MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients
JF - CANCER GENOMICS & PROTEOMICS
VL - 16
IS - 5
SP - 353-359
EP - 353-359
PB - INT INST ANTICANCER RESEARCH
SN - 11096535
KW - Renal cell carcinoma
KW - sunitinib
KW - microRNA
KW - prediction
UR - http://cgp.iiarjournals.org/content/16/5/353.full
L2 - http://cgp.iiarjournals.org/content/16/5/353.full
N2 - Background/Aim: Sunitinib is a tyrosine kinase inhibitor routinely used as first-line therapy in metastatic renal cell carcinoma (mRCC). Emerging evidence suggests that microRNAs (miRNAs) could be suitable biomarkers with predictive potential in mRCC. The aim of this study was to identify miRNA-based predictive biomarkers of therapy response to avoid unnecessary therapy to non-responding patients. Patients and Methods: High-throughput miRNA microarray profiling was performed on a cohort of 47 patients treated with sunitinib. Validation of candidate miRNAs was carried out on an independent cohort of 132 mRCC patients using qRT-PCR. Results: Out of 158 miRNAs (65 down-regulated, 93 up-regulated), six miRNAs were chosen for independent validation and miR-376b-3p was confirmed to be differentially expressed in tumors of patients with primary resistance versus long-term response (p<0.0002). Conclusion: A predictive miRNA associated with progression free survival in metastatic renal cell carcinoma patients treated with sunitinib was identified.
ER -
BOHOŠOVÁ, Júlia, Jaroslav JURÁČEK, Alexandr POPRACH, J. KOPECKY, O. FIALA, Marek SVOBODA, Pavel FABIAN, Lenka RADOVÁ, Petr BRABEC, T. BUCHLER and Ondřej SLABÝ. MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients. \textit{CANCER GENOMICS \&{}amp; PROTEOMICS}. ATHENS: INT INST ANTICANCER RESEARCH, 2019, vol.~16, No~5, p.~353-359. ISSN~1109-6535. Available from: https://dx.doi.org/10.21873/cgp.20140.
|
